Clinical Trials Logo
  1. Home
  2. Dry Eye Syndromes
  3. NCT05598242
  4. Details
NCT05598242 Clinical Trial

Amniotic Membrane Treatment for Hyposecretory Dry Eye

Dry Eye Syndromes Clinical Trial

Official title:
Amniotic Membrane Treatment for Hyposecretory Dry Eye

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05598242
Other study ID # 192 LUPeSe/18 (ENM)
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 1, 2019
Est. completion date December 15, 2019

Study information
Verified date October 2022
Source Hospital Nacional Profesor Alejandro Posadas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized, active-controlled, parallel-group trial is to evaluate the clinical efficacy of amniotic membrane extract eye drops (AMEED) in reducing signs and symptoms of hyposecretory dry eye Participants will receibed amniotic membrane extract eye drops 6 times daily and was evaluated at baseline day and day 30th. Researchers will compare against autologous serum eye drops effects

Description:

This was a randomized, active-controlled, parallel-group trial. The perfect masked conditions could not be accomplished because the autologous serum eye drops needs venous punction for it preparation. During de initial 2 weeks screening period, the patients received artificial tears 4 times daily to minimize the effects of any eye drops used before patients were allocated randomly to receive autologous serum eye drops (ASED) or AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.

Recruitment information / eligibility
Status Completed
Enrollment 37
Est. completion date December 15, 2019
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria: - 21 years of age or older - dry eye related symptoms - Fluorescein Corneal Staining score of 4 or more - Lisamina Green Conjunctival score of 4 or more - a no-anesthesia Schirmer test value at 5' of 10 mm or less Exclusion Criteria: - glaucoma treatment - surgical procedures within 3 months of the baseline evaluation - precense of punctal plug - patients that were human immunodeficiency virus positive

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Amniotic membrane extract eye drops (AMEED)
Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.

Locations
Country Name City State
Argentina Hospital Nacional Posadas El Palomar Buenos Aires
Argentina Hospital Nacional Prof. A. Posadas El Palomar Buenos Aires
Argentina Hospital Nacional Profesor A. Posadas El Palomar Buenos Aires

Sponsors (1)
Lead Sponsor Collaborator
Hospital Nacional Profesor Alejandro Posadas

Country where clinical trial is conducted

Argentina, 

Outcome
Type Measure Description Time frame Safety issue
Primary Lisamina green conjunctival staining changes in the lisamina green conjunctival staining (LGCS) score to demonstrate ocular surface damage 1 month
Secondary Fluorescein Corneal staining fluorescein corneal staining (FCS) score to demostrate corneal ephithelium involment 1 month
Secondary Schirmer's test Schirmer´s test to asses lacrimal production whithout anesthesia 1 month
Secondary TBUT tear film break up time 1 month
Secondary OSDI severity of symptoms reported by patients according to the ocular surface disease index (OSDI) 1 month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A